Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 7 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Amicus Therapeutics Inc. has 11 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 11 examiners across 9 art units, showing broad examiner distribution with some art-unit overlap. LANKFORD JR, LEON B is the busiest examiner, with 1 pending matter.
The action and examiner counts are equal, so the profile does not identify repeated examiner assignments. Counsel should use matter-specific responses while reviewing the shared art units for recurring technical or procedural considerations.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (22%) |
| §102 only | 1 (11%) |
| §112 only | 1 (11%) |
| Multi-statute (no §101) | 4 (44%) |
| No statute on record | 1 (11%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRAUN, MADELINE E | 1 | 68.4% | +25.3% |
| MEAH, MOHAMMAD Y | 1 | 70.7% | +42.8% |
| LOUNTOS, GEORGE THEMISTOCLIS | 1 | 57.1% | +60.0% |
| INAM, SAHAR | 1 | 100.0% | +0.0% |
| STEADMAN, DAVID J | 1 | 57.7% | +29.7% |
| NGUYEN, QUANG | 1 | 37.9% | +52.6% |
| WEHBE, ANNE MARIE SABRINA | 1 | 57.3% | +43.3% |
| LEE, CHIHYI NMN | 1 | 33.3% | +61.1% |
| TSAY, MARSHA M | 1 | 45.5% | +52.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17767803 | VARIANT IGF2 CONSTRUCTS | WEHBE, ANNE MARIE SABRINA | 86d overdue |
| 17773416 | Recombinant CDKL5 Proteins, Gene Therapy and Production Methods | NGUYEN, QUANG | 27d |
| 18040866 | Vesicle Targeting Proteins And Uses Of Same | LOUNTOS, GEORGE THEMISTOCLIS | — |
| 17909450 | Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene | INAM, SAHAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17767803 | VARIANT IGF2 CONSTRUCTS | WEHBE, ANNE MARIE SABRINA | 86d overdue |
| 18111321 | Highly Potent Acid Alpha-Glucosidase With Enhanced Carbohydrates | MEAH, MOHAMMAD Y | 9d overdue |
| 17838741 | Recombinant Alpha-Galactosidase A For Treatment Of Fabry Disease | STEADMAN, DAVID J | 19d |
| 17773416 | Recombinant CDKL5 Proteins, Gene Therapy and Production Methods | NGUYEN, QUANG | 27d |
| 18479396 | METHODS OF TREATING FABRY DISEASE IN PATIENTS HAVING A MUTATION IN THE GLA GENE | BRAUN, MADELINE E | — |
| 18040866 | Vesicle Targeting Proteins And Uses Of Same | LOUNTOS, GEORGE THEMISTOCLIS | — |
| 17424979 | USE OF MIGALOSTAT IN REDUCING THE RISK OF CEREBROVASCULAR EVENT IN PATIENTS WITH FABRY DISEASE | LEE, CHIHYI NMN | — |
| 17079859 | Method To Predict Response To Pharmacological Chaperone Treatment Of Diseases | TSAY, MARSHA M | — |
| Art Unit | Apps |
|---|---|
| 1652 | 2 |
| 1656 | 2 |
| 1624 | 1 |
| 1622 | 1 |
| 1631 | 1 |
| 1634 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18479396 | METHODS OF TREATING FABRY DISEASE IN PATIENTS HAVING A MUTATION IN THE GLA GENE | BRAUN, MADELINE E | 1624 | §102Other | Non-Final OA | — | Pending | Oct 02, 2023 |
| 18111321 | Highly Potent Acid Alpha-Glucosidase With Enhanced Carbohydrates | MEAH, MOHAMMAD Y | 1652 | §112 | Non-Final OA | 9d overdue | Pending | Feb 17, 2023 |
| 18040866 | Vesicle Targeting Proteins And Uses Of Same | LOUNTOS, GEORGE THEMISTOCLIS | 1652 | §102§112 | Non-Final OA | — | Pending | Feb 07, 2023 |
| 17909450 | Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene | INAM, SAHAR | 1622 | §103§112 | Non-Final OA | — | Pending | Sep 06, 2022 |
| 17838741 | Recombinant Alpha-Galactosidase A For Treatment Of Fabry Disease | STEADMAN, DAVID J | 1656 | §103 | Final Rejection | 19d | Pending | Jun 13, 2022 |
| 17773416 | Recombinant CDKL5 Proteins, Gene Therapy and Production Methods | NGUYEN, QUANG | 1631 | §102§103 | Non-Final OA | 27d | Pending | Apr 29, 2022 |
| 17767803 | VARIANT IGF2 CONSTRUCTS | WEHBE, ANNE MARIE SABRINA | 1634 | §103§112 | Final Rejection | 86d overdue | Pending | Apr 08, 2022 |
| 17424979 | USE OF MIGALOSTAT IN REDUCING THE RISK OF CEREBROVASCULAR EVENT IN PATIENTS WITH FABRY DISEASE | LEE, CHIHYI NMN | 1628 | §103Other | Final Rejection | — | Pending | Jul 22, 2021 |
| 17079859 | Method To Predict Response To Pharmacological Chaperone Treatment Of Diseases | TSAY, MARSHA M | 1656 | Other | Non-Final OA | — | Pending | Oct 26, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAmicus Therapeutics Inc. has 9 pending office actions as of October 2026, spread across 7 art units and 9 examiners.
Madeline E Braun has the most, with 1 of Amicus Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
